Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
10.78B
Market cap10.78B
Price-Earnings ratio
-12.46
Price-Earnings ratio-12.46
Dividend yield
Dividend yield
Average volume
3.20M
Average volume3.20M
High today
$87.42
High today$87.42
Low today
$84.63
Low today$84.63
Open price
$85.39
Open price$85.39
Volume
719.64K
Volume719.64K
52 Week high
$88.31
52 Week high$88.31
52 Week low
$32.89
52 Week low$32.89

Stock Snapshot

Cytokinetics(CYTK) stock is priced at $86.65, giving the company a market capitalization of 10.78B. It carries a P/E multiple of -12.46.

As of 2026-07-02, Cytokinetics(CYTK) stock has fluctuated between $84.63 and $87.42. The current price stands at $86.65, placing the stock +2.4% above today's low and -0.9% off the high.

The Cytokinetics(CYTK)'s current trading volume is 719.64K, compared to an average daily volume of 3.2M.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $88.31 and a 52-week low of $32.89.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $88.31 and a 52-week low of $32.89.

CYTK News

Simply Wall St 2d
Cytokinetics Is Up 6.5% After Myqorzo’s Early Commercial Uptake Signals Growing Clinical Interest – Has The Bull Case Changed?

Cytokinetics reported progress in turning its lead heart drug Myqorzo from a development program into an early commercial product, supported by prior regulatory...

Cytokinetics Is Up 6.5% After Myqorzo’s Early Commercial Uptake Signals Growing Clinical Interest – Has The Bull Case Changed?
TipRanks 3d
Top Cytokinetics Executive Makes Bold Insider Moves in High-Value Stock Sales

New insider activity at Cytokinetics ( (CYTK) ) has taken place on June 29, 2026. End of Quarter Sale - 70% Off Unlock powerful investing tools and data-driven...

TipRanks 3d
Cytokinetics upgraded to Buy from Neutral at UBS

UBS analyst Ashwani Verma upgraded Cytokinetics (CYTK) to Buy from Neutral with a price target of $115, up from $69. Cytokinetics is well positioned for upside...

Analyst ratings

91%

of 23 ratings
Buy
91.3%
Hold
8.7%
Sell
0%

More CYTK News

Simply Wall St 5d
Is Cytokinetics Still Cheap After Its Strong Share Price Run?

Cytokinetics (CYTK) has been drawing attention after recent share price moves, with the stock closing at $82.19 and showing double digit total returns over the...

Is Cytokinetics Still Cheap After Its Strong Share Price Run?

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.